CORLYTICS
Corlytics, the global leader in regulatory intelligence and policy compliance technology, has acquired a digital RegTech platform from Deloitte UK. The marriage of the two platforms is transformational, completing the cycle of regulatory assessment and implementation. The announcement closely follows Verdane’s majority stake investment last month to cement Corlytics’ global category leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507401813/en/
John Byrne (Corlytics CEO), Kent Mackenzie (Corlytics COO) (Photo: Business Wire)
Plugged directly into international regulators, Corlytics is the only solution that enables clients to align with, and stay ahead of, regulatory demands, which increasingly require growing levels of proof of compliance.
Syncing up regulatory monitoring and policy management with controls, the addition of this Deloitte UK RegTech platform supports accurate implementation of regulatory change across the lifecycle. This platform and its unique capabilities add considerable breadth and domain expertise to further Corlytics’ capabilities from interpreting regulatory change, to mapping policies and now to controls – empowering users to find, interpret, understand and accurately implement regulatory change.
Corlytics CEO John Byrne said: “This is a transformational acquisition for clients. The RegTech market is growing and evolving fast, and Corlytics is positioned at the forefront. We continue to seek opportunities for sustainable expansion and consolidation, and are thrilled to incorporate this Deloitte UK platform and associated team. Deloitte UK has been using our intelligent data for five years now, and I’m thrilled to take this relationship to the next level. Our ambition goes beyond intelligent data solutioning – we aim to establish a new horizon and set a new standard for how compliance is managed.”
Deloitte UK Partner and Head of RegTech Kent Mackenzie will join Corlytics as Chief Operating Officer.
He added: “The Corlytics business and this Deloitte UK RegTech platform are hugely complimentary, and as a combination can offer a truly unique, end-to-end platform in the market. This is a gamechanger for our clients and the industry. Together, we can completely address the critical challenges clients are desperate to solve, and elevate the value and intelligence placed on regulatory content and management.”
Proven Acquisition and Integration
2023 saw Corlytics make two significant acquisitions – ING SparQ and Clausematch – creating an unparalleled platform that manages the entire regulatory risk value chain on a global scale, elevating its extensive offer for Tier 1 organisations including ING, BNY Mellon, ScotiaBank and SwissRe.
Corlytics continues to invest heavily in innovation, with investments in R&D to date exceeding €65 million.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507401813/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release
With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w
SMBC Group and Jefferies Significantly Expand Their Global Strategic Alliance19.9.2025 10:00:00 CEST | Press release
Joint Venture to Combine Equities and ECM Businesses in JapanExpanding Joint Coverage of Larger SponsorsIn EMEA, Implementing Joint Origination, Underwriting and Execution of Syndicated Leveraged Finance for These ClientsSMBC to Increase Equity Ownership in Jefferies to up to 20% in the Open MarketSMBC to Provide Jefferies Approximately $2.5 Billion in New Credit Facilities to Support Jefferies and to Facilitate Collaboration Efforts Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc. (NYSE: SMFG) (“SMFG”), Sumitomo Mitsui Banking Corporation (“SMBC”), and SMBC Nikko Securities Inc. (“SMBC Nikko”) (collectively, “SMBC Group”) announced today that they are significantly expanding their Global Strategic Alliance. SMBC Group and Jefferies initially entered into a Strategic Alliance in 2021 to collaborate on future corporate and investment banking business opportunities. In 2023, the Alliance was expanded to enhance collaboration across M&A,
REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility19.9.2025 10:00:00 CEST | Press release
Flexible brand options, enhanced aroma, and reduced tobacco consumption empower REJO's ambition in Europe REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/ REJO MULTI Product Launch Event “REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.” “Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom